589 related articles for article (PubMed ID: 25182660)
21. Esomeprazole and rabeprazole did not reduce antiplatelet effects of aspirin/clopidogrel dual therapy in patients undergoing percutaneous coronary intervention: a prospective, randomized, case-control study.
Liu LP; Wang Y; Si R; Yuan M; Cheng K; Guo WY
Expert Opin Pharmacother; 2016; 17(1):7-16. PubMed ID: 26549402
[TBL] [Abstract][Full Text] [Related]
22. The influencing factors for clopidogrel-mediated platelet inhibition are assay-dependent.
Gremmel T; Steiner S; Seidinger D; Koppensteiner R; Panzer S; Kopp CW
Thromb Res; 2011 Oct; 128(4):352-7. PubMed ID: 21621250
[TBL] [Abstract][Full Text] [Related]
23. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
[TBL] [Abstract][Full Text] [Related]
24. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
[TBL] [Abstract][Full Text] [Related]
25. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
26. Association between insulin receptor substrate-1 polymorphisms and high platelet reactivity with clopidogrel therapy in coronary artery disease patients with type 2 diabetes mellitus.
Zhang D; Zhang X; Liu D; Liu T; Cai W; Yan C; Han Y
Cardiovasc Diabetol; 2016 Mar; 15():50. PubMed ID: 27005817
[TBL] [Abstract][Full Text] [Related]
27. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Nardin M; Verdoia M; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
Nutr Metab Cardiovasc Dis; 2016 Jul; 26(7):567-574. PubMed ID: 27134063
[TBL] [Abstract][Full Text] [Related]
28. The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.
Gurbel PA; Shuldiner AR; Bliden KP; Ryan K; Pakyz RE; Tantry US
Am Heart J; 2011 Mar; 161(3):598-604. PubMed ID: 21392617
[TBL] [Abstract][Full Text] [Related]
29. Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.
Jeong YH; Hwang JY; Kim IS; Park Y; Hwang SJ; Lee SW; Kwak CH; Park SW
Circ Cardiovasc Interv; 2010 Feb; 3(1):17-26. PubMed ID: 20118150
[TBL] [Abstract][Full Text] [Related]
30. Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.
Cecchi E; Marcucci R; Chiostri M; Mecarocci V; Spini V; Innocenti L; Calabretta R; Cordisco A; Romano SM; Abbate R; Gensini GF; Giglioli C
Intern Emerg Med; 2015 Oct; 10(7):805-14. PubMed ID: 25944129
[TBL] [Abstract][Full Text] [Related]
31. Response to antiplatelet therapy is independent of endogenous thrombin generation potential.
Gremmel T; Panzer S; Steiner S; Seidinger D; Koppensteiner R; Pabinger I; Kopp CW; Ay C
Thromb Res; 2013 Jul; 132(1):e24-30. PubMed ID: 23623170
[TBL] [Abstract][Full Text] [Related]
32. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
[TBL] [Abstract][Full Text] [Related]
33. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis.
Blindt R; Stellbrink K; de Taeye A; Müller R; Kiefer P; Yagmur E; Weber C; Kelm M; Hoffmann R
Thromb Haemost; 2007 Dec; 98(6):1329-34. PubMed ID: 18064332
[TBL] [Abstract][Full Text] [Related]
34. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
[TBL] [Abstract][Full Text] [Related]
35. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.
Jakubowski JA; Payne CD; Li YG; Farid NA; Brandt JT; Small DS; Salazar DE; Winters KJ
Thromb Haemost; 2008 Jan; 99(1):215-22. PubMed ID: 18217157
[TBL] [Abstract][Full Text] [Related]
36. Platelet turnover predicts outcome after coronary intervention.
Freynhofer MK; Iliev L; Bruno V; Rohla M; Egger F; Weiss TW; Hübl W; Willheim M; Wojta J; Huber K
Thromb Haemost; 2017 May; 117(5):923-933. PubMed ID: 28229159
[TBL] [Abstract][Full Text] [Related]
37. Platelet Inhibition and Bleeding in Patients Undergoing Non-Cardiac Surgery-The BIANCA Observational Study.
Mahla E; Metzler H; Bornemann-Cimenti H; Prueller F; Raggam RB; Pregartner G; Berghold A; Baumann A; Goeroeg C; Gurbel PA
Thromb Haemost; 2018 May; 118(5):864-872. PubMed ID: 29625498
[TBL] [Abstract][Full Text] [Related]
38. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
[TBL] [Abstract][Full Text] [Related]
39. The effect of esomeprazole vs famotidine on aspirin/clopidogrel dual therapy after percutaneous coronary intervention.
Wu Y; Chen C; Luo Y; Yu W; Huang S; Lin D
Adv Clin Exp Med; 2019 Nov; 28(11):1519-1524. PubMed ID: 31660706
[TBL] [Abstract][Full Text] [Related]
40. Doubling the clopidogrel dose in patients with reduced responsiveness to the standard dose is associated with a limited effectiveness as evaluated by impedance aggregometry.
Stellbaum C; Ayral Y; Morguet A; Schultheiss HP; Rauch U
Cardiovasc Revasc Med; 2012; 13(3):159-66. PubMed ID: 22503564
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
